LSTA
Price
$3.05
Change
+$0.34 (+12.55%)
Updated
Dec 23, 04:48 PM (EDT)
94 days until earnings call
NERV
Price
$2.12
Change
-$0.04 (-1.85%)
Updated
Dec 23, 04:50 PM (EDT)
85 days until earnings call
Ad is loading...

LSTA vs NERV

Header iconLSTA vs NERV Comparison
Open Charts LSTA vs NERVBanner chart's image
Lisata Therapeutics
Price$3.05
Change+$0.34 (+12.55%)
Volume$200
CapitalizationN/A
Minerva Neurosciences
Price$2.12
Change-$0.04 (-1.85%)
Volume$100
CapitalizationN/A
LSTA vs NERV Comparison Chart
Loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LSTA vs. NERV commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LSTA is a Hold and NERV is a Hold.

COMPARISON
Comparison
Dec 24, 2024
Stock price -- (LSTA: $2.71 vs. NERV: $2.16)
Brand notoriety: LSTA and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LSTA: 108% vs. NERV: 160%
Market capitalization -- LSTA: $25.35M vs. NERV: $14.83M
LSTA [@Biotechnology] is valued at $25.35M. NERV’s [@Biotechnology] market capitalization is $14.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $363.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LSTA’s FA Score shows that 1 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • LSTA’s FA Score: 1 green, 4 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, LSTA is a better buy in the long-term than NERV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LSTA’s TA Score shows that 1 TA indicator(s) are bullish while NERV’s TA Score has 4 bullish TA indicator(s).

  • LSTA’s TA Score: 1 bullish, 5 bearish.
  • NERV’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NERV is a better buy in the short-term than LSTA.

Price Growth

LSTA (@Biotechnology) experienced а +5.04% price change this week, while NERV (@Biotechnology) price change was -2.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.79%. For the same industry, the average monthly price growth was -2.59%, and the average quarterly price growth was +3.59%.

Reported Earning Dates

LSTA is expected to report earnings on Mar 27, 2025.

NERV is expected to report earnings on Mar 18, 2025.

Industries' Descriptions

@Biotechnology (-1.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LSTA($25.4M) has a higher market cap than NERV($14.8M). LSTA YTD gains are higher at: -0.733 vs. NERV (-64.878). NERV has higher annual earnings (EBITDA): 3.47M vs. LSTA (-23.31M). LSTA has more cash in the bank: 35.9M vs. NERV (26.5M). NERV has less debt than LSTA: NERV (0) vs LSTA (181K). LSTA (0) and NERV (0) have equivalent revenues.
LSTANERVLSTA / NERV
Capitalization25.4M14.8M172%
EBITDA-23.31M3.47M-672%
Gain YTD-0.733-64.8781%
P/E RatioN/AN/A-
Revenue00-
Total Cash35.9M26.5M135%
Total Debt181K0-
FUNDAMENTALS RATINGS
LSTA vs NERV: Fundamental Ratings
LSTA
NERV
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
7865
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (14) in the null industry is somewhat better than the same rating for NERV (57) in the Biotechnology industry. This means that LSTA’s stock grew somewhat faster than NERV’s over the last 12 months.

LSTA's Profit vs Risk Rating (100) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that LSTA’s stock grew similarly to NERV’s over the last 12 months.

LSTA's SMR Rating (97) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that LSTA’s stock grew similarly to NERV’s over the last 12 months.

NERV's Price Growth Rating (65) in the Biotechnology industry is in the same range as LSTA (78) in the null industry. This means that NERV’s stock grew similarly to LSTA’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that NERV’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LSTANERV
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
89%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 15 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 4 days ago
85%
View a ticker or compare two or three
Ad is loading...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BARK1.980.05
+2.59%
BARK
CNS92.491.82
+2.01%
Cohen & Steers
EQ0.610.01
+1.33%
Equillium
SII42.410.06
+0.14%
Sprott
ROL46.92-0.09
-0.19%
Rollins

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and ASND have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and ASND's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
+7.54%
ASND - LSTA
26%
Poorly correlated
-0.99%
MRUS - LSTA
25%
Poorly correlated
-0.57%
AMLX - LSTA
25%
Poorly correlated
+2.27%
MDGL - LSTA
25%
Poorly correlated
+5.12%
PRME - LSTA
24%
Poorly correlated
+3.94%
More